1,000 Layoffs Expected At Novo Nordisk As US Pricing Pressures Bite
Executive Summary
As a parting gift to Novo Nordisk staff, outgoing CEO Lars Rebien Sørensen has announced 1,000 job cuts at the company – around half in its home country of Denmark – in order to create a "sustainable balance between income and costs" in preparation for a challenging 2017.
You may also be interested in...
Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures
Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.